Advanced search
Publication Cover
Diabetes, Metabolic Syndrome and Obesity Volume 13, 2020 - Issue
Submit an article Journal homepage
117
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

Robert Thomann1 Bürgerspital Solothurn, Solothurn, SwitzerlandView further author information
,
Stefan Zechmann2 Institute of Primary Care, University of Zurich, Zurich, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-5012-0068View further author information
ORCID Icon,
Nicola Alexander-David3 Private Practice, Bellinzona, SwitzerlandView further author information
&
François R Jornayvaz4 Hôpitaux Universitaires de Genève, Geneva, SwitzerlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9425-3137View further author information
ORCID Icon
Pages 2359-2365 | Published online: 03 Jul 2020

References

  • Schimke KE, Renstrom F, Meier S, Stettler C, Brandle M, SwissDiab Study G. Compliance with guidelines for disease management in diabetes: results from the SwissDiab registry. BMJ Open Diabetes Res Care. 2018;6:e000454. doi:10.1136/bmjdrc-2017-000454
  • Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Jarvinen H. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018;20(3):541–548. doi:10.1111/dom.13105
  • Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386–394. doi:10.1111/dom.12438
  • Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40(11):1425–1432. doi:10.2337/dc16-1974
  • Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence — what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297. doi:10.1056/NEJMsb1609216
  • Zhou FL, Ye F, Berhanu P, et al. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes Obes Metab. 2018;20(5):1293–1297. doi:10.1111/dom.13199
  • Pfohl M, Jornayvaz FR, Fritsche A, et al. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes after failure of oral therapy in a real-world setting. Diabetes Obes Metab. 2020;22(5):759–766. doi:10.1111/dom.13952
  • Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in Insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018;41(10):2147–2154. doi:10.2337/dc18-0559
  • Sullivan SD, Nicholls CJ, Gupta RA, et al. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: the DELIVER Naïve D real-world study. Diabetes Obes Metab. 2019;21(9):2123–2132. doi:10.1111/dom.13793
  • Wiesli P, Schories M. Improved glycemic control with insulin glargine 300 U/mL (Toujeo®) in patients with type 2 diabetes: real-world effectiveness in Switzerland. Diabetes Ther. 2018;9(6):2325–2334. doi:10.1007/s13300-018-0518-x

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.